-Bloomberg
CinCor Pharma Doses First Patient In Phase 2 FigHTN-CKD Trial Evaluating The Selective Aldosterone Synthase Inhibitor Baxdrostat In Patients With Uncontrolled Hypertension And Chronic Kidney Disease
CinCor Pharma, Inc. (“CinCor”) announced today that the first patient has been dosed in the Phase 2 figHTN-CKD trial evaluating baxdrostat (CIN-107), a highly selective aldosterone synthase inhibitor, in